International Stem Cell Corp., a California-based biotech
company developing novel stem cell-based therapies and biomedical products,
today issued a business update and posted its financial results for the first
quarter of 2015.
Business updates for the first quarter of the year include:
• Completed
the required preclinical studies and submitted a clinical trial exemption
application to the Australian Therapeutics Goods Administration (TGA) to begin
the phase 1/2a clinical study of the company’s cell therapy for the treatment
of Parkinson’s disease. To be administered through the company’s wholly owned
Australian subsidiary, Cyto Therapeutics Pty Ltd.
• Completed
the manufacture of the bank of clinical-grade human neural stem cells for use
in the Parkinson’s disease clinical trial. The cell bank contains more than 2.6
billion human cells, sufficient to meet the company’s foreseeable clinical
trial requirements.
• Japan
Patent Office granted International Stem Cell’s patent covering methods of
making a bank of human stem cells from parthenogenetically activated eggs
significantly strengthening and expanding the company’s intellectual property
to now include Japan as well as the United States and the European Union.
“In the first quarter of 2015 we completed all the necessary
preclinical studies of our Parkinson’s program and formally submitted our
application to begin the first clinical study of this novel approach to
treating this debilitating disease in humans,” Andrey Semechkin, Ph.D., CEO and
Co-chairman of International Stem Cell, stated in the news release. “We
continue to expect to make significant progress during the rest of 2015 towards
our goal of providing a viable treatment options for people with Parkinson’s
disease.”
On the financial side, International Stem Cell achieved
first-quarter revenue of $1.62 million; Lifeline Skin Care increased 5% while
Lifeline Cell Technology sales decreased by 8%. Operating income from
cosmeceutical and biomedical markets grew 76% compared with the first quarter
of 2014. Gross margin improved to 74%
The company narrowed its first-quarter 2015 net loss to
$1.29 million compared to a net loss of $1.44 million reported in the year ago
quarter. International Stem Cell ended the first quarter of 2015 with cash of
$0.61 million.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment